Proficio Capital Partners LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

Proficio Capital Partners LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 61.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 3,053 shares of the company’s stock after acquiring an additional 1,157 shares during the quarter. Proficio Capital Partners LLC’s holdings in Zoetis were worth $497,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the period. Dunhill Financial LLC grew its stake in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Asset Planning Inc purchased a new stake in Zoetis during the 4th quarter worth about $58,000. Quarry LP raised its position in Zoetis by 45.9% in the 3rd quarter. Quarry LP now owns 305 shares of the company’s stock valued at $60,000 after purchasing an additional 96 shares in the last quarter. Finally, Wingate Wealth Advisors Inc. acquired a new stake in Zoetis in the 4th quarter valued at about $63,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.1 %

ZTS stock opened at $163.22 on Tuesday. The company has a 50 day moving average price of $166.70 and a two-hundred day moving average price of $175.22. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market capitalization of $73.09 billion, a P/E ratio of 29.84, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.33.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.23%. Zoetis’s payout ratio is 36.56%.

Analysts Set New Price Targets

ZTS has been the subject of a number of recent research reports. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Piper Sandler boosted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $215.90.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,862 shares of company stock valued at $312,254. Insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.